Theravance Biopharma

Yahoo Finance • 2 days ago

Small-cap healthcare stocks with A+ grade EPS revisions ahead of earnings

[Health Care Medical Stock Market Industry Sector Wall Street Buildings 3d Illustration] iQoncept/iStock via Getty Images As Q1 2026 earnings season approaches, the healthcare sector enters reporting season as one of the market's primary... Full story

Yahoo Finance • 4 days ago

TBPH Investors Have Opportunity to Join Theravance Biopharma, Inc. Fraud Investigation with the Schall Law Firm

LOS ANGELES, April 08, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Theravance Biopharma, Inc. (“Theravance” or “the Comp... Full story

Yahoo Finance • last month

Theravance drops rare disease drug after late-stage trial setback

[Red arrow And dollar finance decline graph- Stock image] Baris-Ozer Theravance Biopharma (TBPH [https://seekingalpha.com/symbol/TBPH]) announced on Tuesday that it will halt its clinical program for its rare disease therapy ampreloxetine... Full story

Yahoo Finance • 2 months ago

Vistance Networks Stock Up 250%. Here's Why a $40 Million Position Signals a Post-Divestiture Bet

On February 17, 2026, Newtyn Management bought 1.6 million shares of Vistance Networks(NASDAQ:VISN) in the fourth quarter. What happened According to a Securities and Exchange Commission (SEC) filing dated February 17, 2026, Newtyn Manag... Full story

Yahoo Finance • 2 months ago

Array Stock Down 25%, But This $17.3 Million Buy Signals Confidence Amid Big Revenue Growth

On February 17, 2026, Newtyn Management disclosed a buy of 350,000 shares of Array Digital Infrastructure(NYSE:AD), an estimated $17.3 million trade based on quarterly average pricing. What happened According to an SEC filing dated Febru... Full story

Yahoo Finance • 2 months ago

Enviri Stock Up 120% as $43 Million Buy Makes It a Top Holding in This Portfolio

Newtyn Management reported a buy of 2,906,420 shares of Enviri Corporation(NYSE:NVRI) in its February 17, 2026, SEC filing, an estimated $43.31 million transaction based on average quarterly pricing. What happened According to a SEC fili... Full story

Yahoo Finance • 2 months ago

Integer Stock Down 38%, but One Fund Just Bet $40 Million on a Turnaround

On February 17, 2026, Newtyn Management disclosed a new position in Integer Holdings(NYSE:ITGR), acquiring 550,000 shares worth an estimated $43.14 million. What happened According to an SEC filing dated February 17, 2026, Newtyn Managem... Full story

Yahoo Finance • 2 months ago

Irenic Dumps Most Papa John's Shares

According to an SEC filing dated Feb. 17, Irenic Capital Management LP reduced its position in Papa John's International(NASDAQ:PZZA)by 748,592 shares. The fund’s remaining stake, reported at quarter-end, was 325,108 shares worth $12.51 mi... Full story

Yahoo Finance • 4 months ago

Millrose Properties Stock Has Surged 48% Since February Debut — So Why Did One Investor Sell a $23 Million Stake?

Key Points New York City-based Newtyn Management sold 807,135 shares of Millrose Properties, reducing its position by $23 million in the third quarter. The transaction represented approximately 2.8% of reported 13F assets under management... Full story

Yahoo Finance • 4 months ago

Why One Investor Bought $67.5 Million in Array Digital Infrastructure Stock

Key Points New York City-based Newtyn Management added 1.35 million shares of Array Digital Infrastructure, an estimated $67.5 million trade based on quarterly average pricing. The position change represents 8.3% of 13F reportable assets... Full story

Yahoo Finance • 4 months ago

Why One Value Fund Has a $101 Million Bet on Indivior Stock Amid a 212% Surge

Key Points New York City-based Newtyn Management increased its stake in Indivior by nearly 1.6 million shares in the third quarter, resulting in a net position change of $62.8 million. The transaction represents a nearly 4.1% change in 13... Full story

Yahoo Finance • 8 months ago

Theravance Biopharma stock rating reiterated at Buy by BTIG

Investing.com - Theravance Biopharma (NASDAQ:TBPH) received a reiterated Buy rating from BTIG, which maintained its $25.00 price target on the stock. The target represents significant upside potential from the current price of $13.80, with... Full story

Yahoo Finance • 8 months ago

Theravance anticipates $150M in milestones as CYPRESS trial nears pivotal data readout

Earnings Call Insights: Theravance Biopharma, Inc. (TBPH) Q2 2025 MANAGEMENT VIEW * CEO Rick E. Winningham highlighted "an excellent quarter, underscored by disciplined execution across our commercial and development organizations, whi... Full story

Yahoo Finance • 8 months ago

Theravance Biopharma Q2 2025 slides: Revenue jumps 22%, cash position triples

Introduction & Market Context Theravance Biopharma (NASDAQ:TBPH) presented its second quarter 2025 financial results on August 12, showing significant improvement from its first quarter performance. The company’s stock closed at $11.40, u... Full story

Yahoo Finance • 9 months ago

Theravance Biopharma SVP Farnum sells $113,869 in stock

Rhonda Farnum, SVP, COMM & MEDICAL AFFAIRS at Theravance Biopharma, Inc. (NASDAQ:TBPH), sold 10,000 shares of company stock on July 14, 2025, according to a recent SEC Filing. The sales, executed in three separate transactions, fetched a t... Full story

Yahoo Finance • 9 months ago

Viatris Gains China Approval for COPD Drug Yupelri, Triggers $7.5M Payment to Theravance BioPharma

Viatris Inc. (NASDAQ:VTRS) is one of the best low priced pharma stocks to buy now. On June 27, Viatris received approval from China’s National Medical Products Administration/NMPA for Yupelri (revefenacin) inhalation solution for the maint... Full story

Yahoo Finance • 10 months ago

Theravance higher as China approves Viatris-partnered COPD therapy

[Wooden Approved Stamp] kemalbas Theravance Biopharma (NASDAQ:TBPH [https://seekingalpha.com/symbol/TBPH]) added ~7% in the premarket on Thursday after the company announced that China approved its Viatris (NASDAQ:VTRS [https://seekingalp... Full story

Yahoo Finance • 10 months ago

China approves Theravance's YUPELRI for COPD treatment

DUBLIN - China’s National Medical Products Administration (NMPA) has approved YUPELRI (revefenacin) inhalation solution as the first once-daily nebulized long-acting muscarinic antagonist for maintenance treatment of chronic obstructive pu... Full story

Yahoo Finance • 10 months ago

Theravance and Mylan settle patent dispute with Eugia Pharma

[Close-up of accusation and protection sides with juridical documents] AnnaStills Theravance Biopharma (NASDAQ:TBPH [https://seekingalpha.com/symbol/TBPH]) and partner Mylan reached a settlement agreement with Eugia Pharma over a patent d... Full story

Yahoo Finance • 3 years ago

12 High Growth Value Stocks to Buy According to Seth Klarman

In this article, we will take a look at the 12 high growth value stocks to buy according to Seth Klarman. To see more such companies, go directly to 5 High Growth Value Stocks to Buy According to Seth Klarman. Following clear signals from... Full story